Not logged in Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249. Finn, Richard S.; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B.; Qin, Shukui Share Save
Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC) Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B. Share Save
Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC) Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; Dayyani, F.; Yoon, J-H.; Chiu, C-F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B. Share Save
A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer Mao, Chenyu; He, Ye; Xu, Nong; Yan, Haijiao; Zhang, Ningling; Cheng, Gang; Jiang, Hua; Chen, Minbin; Chen, Yong; Wang, Xiaoguang; Gu, Yulan; Shen, Peng; Zhang, Guifang; Yan, Jun; Yang, Zhe; Ding, Lifang; Han, Zhengxiang; Wang, Zhanggui; Zhang, Junqi; Zheng, Weie; Wang, Jufeng; Qin, Shukui Share Save
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial Wang, Feng; Shen, Lin; Guo, Weijian; Liu, Tianshu; Li, Jin; Qin, Shukui; Bai, Yuxian; Chen, Zhendong; Wang, Jufeng; Pan, Yueyin; Shu, Yongqian; Zhao, Fuyou; Cheng, Ying; Ye, Feng; Gu, Kangsheng; Zhang, Tao; Pan, Hongming; Zhong, Haijun; Zhou, Fuxiang; Qin, Yanru; Yang, Lei; Mao, Weidong; Li, Qiu; Dai, Wenxiang; Li, Wei; Wang, Shubin; Tang, Yong; Ma, Dong; Yin, Xianli; Deng, Yanhong; Yuan, Ying; Li, Man; Hu, Wenwei; Chen, Donghui; Li, Guoxin; Liu, Qiqi; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Xu, Rui-Hua Share Save
Share Save
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study Yau, Thomas; Kaseb, Ahmed; Cheng, Ann-Lii; Qin, Shukui; Zhu, Andrew X.; Chan, Stephen L.; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Milwee, Steven; Wang, Zhong; Curran, Dominic; Kelley, Robin Kate; Rimassa, Lorenza Share Save
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study Finn, Richard S.; Kudo, Masatoshi; Barnes, Gisoo; Meyer, Tim; Boisserie, Frederic; Abdrashitov, Ramil; Chen, Yaxi; Li, Songzi; Zhu, Andrew X.; Qin, Shukui; Vogel, Arndt Share Save
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394 Qin, Shukui; Fang, Weijia; Ren, Zhenggang; Ou, Shuangyan; Lim, Ho Yeong; Zhang, Feng; Lee, Kin Chung; Choi, Hye Jin; Tong, Jiandong; Tao, Min; Xu, Aibing; Cheng, Ashley; Lu, Chang-Hsien; Chiu, Chang-Fang; Wahid, Mohamed Ibrahim Abdul; Kamble, Shital; Norquist, Josephine M.; Zhong, Wenyan; Li, Chen; Chen, Zhendong Share Save
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial Qin, Shukui; Chen, Minshan; Cheng, Ann-Lii; Kaseb, Ahmed; Kudo, Masatoshi; Lee, Han Chu; Yopp, Adam C.; Zhou, Jian; Wang, Lu; Wen, Xiaoyu; Heo, Jeong; Tak, Won Young; Nakamura, Shinichiro; Numata, Kazushi; Uguen, Thomas; Hsiehchen, David; Cha, Edward; Hack, Stephen P.; Lian, Qinshu; Ma, Ning; Spahn, Jessica H.; Wang, Yulei; Wu, Chun; Chow, Pierce K. H. Share Save
Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; Lugowska, I.; Carranza, O.; Gutierrez, M.; Winter, H.; Sweiti, H.; Thomas, S.; Gormley, M.; Zhang, J.; Triantos, S.; Schuler, M. H. H. Share Save
Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/ GEJC) Li, J.; Bai, Y.; Chen, Z.; Ying, J.; Guo, Y.; Fang, W.; Zhang, F.; Xiong, J.; Zhang, T.; Meng, Z.; Zhang, J.; Yu, F.; Zhang, J.; Zhang, Z.; Qin, S. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
.png){kind=icon}
Share.png){kind=icon}
Save